GSEA of RNA-seq data of mammary tumors of a size of 1500 mm3 from these four GEMMs showed a clear reduction of immune signatures in the WP-Myc and WB1P-Myc tumors with engineered MYC overexpression, when compared to WP and WB1P control tumors (Fig. 2A). The gene discussed is MYC; the disease is breast cancer.